Characteristics of the development and validation cohortsa
| Development (n = 409) | Validation (n = 317) | P Value | |
|---|---|---|---|
| Age (mean) (SD) (yr) | 57 (13) | 59 (14) | .05 |
| Female sex | 277 (68) | 222 (70) | .5 |
| History of hypertension | 131 (35) | 96 (31) | .2 |
| History of cardiovascular disease | 75 (20) | 61 (20) | 1 |
| History of diabetes | 25 (7) | 18 (6) | .6 |
| WFNS score | .04 | ||
| I | 182 (46) | 106 (39) | |
| II | 51 (13) | 37 (14) | |
| III | 12 (3) | 9 (3) | |
| IV | 68 (17) | 40 (15) | |
| V | 81 (21) | 74 (27) | |
| Aneurysm location | .44 | ||
| Anterior circulation | 324 (79) | 243 (82) | |
| Posterior circulation | 85 (21) | 54 (18) | |
| Aneurysm size (median) (IQR) (mm) | 6 (4–9) | 5 (4–8) | .96 |
| Aneurysm treatment | <.001 | ||
| Coiling | 273 (67) | 153 (48) | |
| Clipping | 64 (16) | 95 (30) | |
| No treatment | 72 (18) | 69 (22) | |
| Total blood volume (median) (IQR) (mL) | 29 (12–60) | 26 (9–51) | .36 |
| Cisternal blood volume (median) (IQR) (mL) | 20 (8–41) | 18 (6–34) | .1 |
| Intraventricular blood volume (median) (IQR) (mL) | 0.5 (0–2) | 0.3 (0–2) | .1 |
| Intraparenchymal blood volume (median) (IQR) (mL) | 0 (0–3) | 0 (0–3) | .8 |
| Modified Fisher grade | .15 | ||
| 0 | 20 (5) | 12 (4) | |
| 1 | 26 (6) | 9 (3) | |
| 2 | 7 (2) | 8(3) | |
| 3 | 92 (23) | 83 (27) | |
| 4 | 262 (64) | 201 (64) | |
| Clinical DCI | 109 (27) | 61 (29) | .6 |
Note:—DCI indicates delayed cerebral ischemia.
↵a All values are in No. (%) unless otherwise indicated.